Home/Biosimilar Atlas/Companies/Norbitec

Norbitec

Biosimilar developer, Germany. 1 development product across 1 molecule: epoetin alfa and zeta.

First approval in the Atlas: Dec 2007, Retacrit, epoetin alfa and zeta (EMA)
FDAproducts approved1
EMAproducts approved1
MHRAproducts approved1
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered0
Connections
1molecule1product3 of 7markets0candidates in trials5companies on the same molecules

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
Epoetin alfa and zetaRetacrit / SilapoMay 2018Dec 2007MHRA····3/7

Month shown is the first approval or registration of that product in that market.

Companies on the same molecules

Developers whose portfolios overlap most with Norbitec, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

Bioviz TechnologiesOne shared molecule: epoetin alfa and zeta1 molecule in its portfolioJCR PharmaceuticalsOne shared molecule: epoetin alfa and zeta3 molecules in its portfolioSandozOne shared molecule: epoetin alfa and zeta10 molecules in its portfolioWockhardtOne shared molecule: epoetin alfa and zeta3 molecules in its portfolioZydus LifesciencesOne shared molecule: epoetin alfa and zeta11 molecules in its portfolio

Chronology

Compare Norbitec with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.